Evidence map›Paper›PMID 21909135›Full record

ArticleOncogene2012

Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of metastasis.

V Walia, Y Yu, D Cao, M Sun, J R McLean, B G Hollier, J Cheng, S A Mani, K Rao, L Premkumar and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

V WaliaDepartment of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL 19629, USA.
Y Yu
D Cao
M Sun
J R McLean
B G Hollier
J Cheng
S A Mani
K Rao
L Premkumar
R C Elble
Southern Illinois University School of Medicine · USNational Institutes of Health · USQueensland University of Technology · AUThe University of Texas MD Anderson Cancer Center · USUniversity of Chicago · USVanderbilt University · US

Funding

A Novel Approach for Chronic Pain Treatment Using ResiniferatoxinR01DA028017 · NIDA · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI PREMKUMAR, LOUIS S · 2009 to 2013
$1.4M
Vanilloid Receptors in Diabetic Peripheral NeuropathyR01DK065742 · NIDDK · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI PREMKUMAR, LOUIS S · 2004 to 2006
$766k
A novel biotherapeutic for triple-negative breast cancer.R15CA151094 · NCI · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI ELBLE, RANDOLPH C · 2010 to 2010
$437k
Role of Vanilloid Receptors in Diabetic Peripheral NeuropathyR56DK065742 · NIDDK · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI PREMKUMAR, LOUIS S · 2008 to 2008
$73k
NCI NIH HHS 1R15CA151094-01NCI NIH HHS R15 CA151094NIDA NIH HHS DA028017NIDA NIH HHS R01 DA028017NIDDK NIH HHS DK065742NIDDK NIH HHS R01 DK065742NIDDK NIH HHS R56 DK065742
6 · The paper itself

Abstract

Transition between epithelial and mesenchymal states is a feature of both normal development and tumor progression. We report that expression of chloride channel accessory protein hCLCA2 is a characteristic of epithelial differentiation in the immortalized MCF10A and HMLE models, while induction of epithelial-to-mesenchymal transition by cell dilution, TGFβ or mesenchymal transcription factors sharply reduces hCLCA2 levels. Attenuation of hCLCA2 expression by lentiviral small hairpin RNA caused cell overgrowth and focus formation, enhanced migration and invasion, and increased mammosphere formation in methylcellulose. These changes were accompanied by downregulation of E-cadherin and upregulation of mesenchymal markers such as vimentin and fibronectin. Moreover, hCLCA2 expression is greatly downregulated in breast cancer cells with a mesenchymal or claudin-low profile. These observations suggest that loss of hCLCA2 may promote metastasis. We find that higher-than-median expression of hCLCA2 is associated with a one-third lower rate of metastasis over an 18-year period among breast cancer patients compared with lower-than-median (n=344, unfiltered for subtype). Thus, hCLCA2 is required for epithelial differentiation, and its loss during tumor progression contributes to metastasis. Overexpression of hCLCA2 has been reported to inhibit cell proliferation and is accompanied by increases in chloride current at the plasma membrane and reduced intracellular pH (pHi). We found that knockdown cells have sharply reduced chloride current and higher pHi, both characteristics of tumor cells. These results suggest a mechanism for the effects on differentiation. Loss of hCLCA2 may allow escape from pHi homeostatic mechanisms, permitting the higher intracellular and lower extracellular pH that are characteristic of aggressive tumor cells.

Indexed as

Epithelial-Mesenchymal TransitionBiomarkersBreast NeoplasmsCell DifferentiationCell Line, TumorChloride ChannelsFemaleHumansHydrogen-Ion ConcentrationNeoplasm MetastasisBiomarkersChloride ChannelsCLCA2 protein, human

Identifiers

PMID21909135
PMCPMC4154589
OpenAlexW1548519423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.